These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cost containment through P & T committee drug utilization review. Bender FH; DeMatteo CS Hosp Formul; 1984 Aug; 19(8):699-700, 705-7. PubMed ID: 10267391 [TBL] [Abstract][Full Text] [Related]
23. Estimated position replacement costs for technician personnel in a state's public facilities. Zaharia ES; Baumeister AA Ment Retard; 1978 Apr; 16(2):131-4. PubMed ID: 565456 [No Abstract] [Full Text] [Related]
24. Differences in the cost of antidepressants across state Medicaid programs. Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875 [TBL] [Abstract][Full Text] [Related]
25. Pennsylvania welfare patients get prescriptions from formulary. Hospitals; 1967 Sep; 41(18):108. PubMed ID: 6073606 [No Abstract] [Full Text] [Related]
27. The effect of a closed formulary on prescription drug use and costs. Motheral BR; Henderson R Inquiry; 1999-00 Winter; 36(4):481-91. PubMed ID: 10711322 [TBL] [Abstract][Full Text] [Related]
28. Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. Chaudhury RR; Parameswar R; Gupta U; Sharma S; Tekur U; Bapna JS Health Policy Plan; 2005 Mar; 20(2):124-36. PubMed ID: 15746221 [TBL] [Abstract][Full Text] [Related]
29. Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors. Wang YR; Pauly MV Manag Care Interface; 2005 Aug; 18(8):39-45. PubMed ID: 16127891 [TBL] [Abstract][Full Text] [Related]
30. Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment. Sheehan DV; Wright-Etter PJ Manag Care Q; 2002; 10(3):21-31. PubMed ID: 12476662 [TBL] [Abstract][Full Text] [Related]
31. Implementing and using quality measures for children's health care: perspectives on the state of the practice. Shaller D Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504 [TBL] [Abstract][Full Text] [Related]
32. Smoke-free policies in the psychiatric population on the ward and beyond: a discussion paper. Green MA; Hawranik PG Int J Nurs Stud; 2008 Oct; 45(10):1543-9. PubMed ID: 18304553 [TBL] [Abstract][Full Text] [Related]
33. Comparison of states' utilization of large residential settings for persons with mental retardation. Rotholz DA; Massey PS Ment Retard; 1996 Oct; 34(5):303-11. PubMed ID: 8908995 [TBL] [Abstract][Full Text] [Related]
34. Implementation of clinical pharmacy services: rationalizing drug therapy in a mental retardation facility. Inoue F Hosp Formul; 1978 Apr; 13(4):278-81, 284. PubMed ID: 10306918 [No Abstract] [Full Text] [Related]
35. Formulary management to reduce cost: P & T committee strategies. Roberts MJ; Summerfield MR Hosp Formul; 1986 Apr; 21(4):481-3, 488-92. PubMed ID: 10276289 [TBL] [Abstract][Full Text] [Related]
36. Managing high cost and biotech drugs: two institutions' perspectives. Dana WJ; McWhinney B Hosp Formul; 1994 Sep; 29(9):638-45. PubMed ID: 10137060 [TBL] [Abstract][Full Text] [Related]
37. Helping youths on the streets. What one shelter has learned from years of experience. Prewitt LD Behav Healthc; 2006 May; 26(5):46-7. PubMed ID: 16736922 [No Abstract] [Full Text] [Related]
38. Reinventing the government role in pharmacotherapy. Bougher DJ Can J Clin Pharmacol; 2001; 8 Suppl A():45A-47A. PubMed ID: 11586379 [TBL] [Abstract][Full Text] [Related]
39. Materials management in multi-facility systems: a case study. Cohen N; Leventhal EA Hosp Purch Manage; 1984 Sep; 9(9):3-10. PubMed ID: 10267818 [TBL] [Abstract][Full Text] [Related]
40. Emerging lessons from the drug effectiveness review project. Neumann PJ Health Aff (Millwood); 2006; 25(4):W262-71. PubMed ID: 16757486 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]